Allan Basbaum

Solace Pharmaceuticals, Inc. develops therapies for the treatment of neuropathic pain. It offers therapies for neuropathic and inflammatory pain. It offers discovery and development of innovative therapies for pain through in-house drug discovery and development programs as well as through selected partnerships. The company was founded in March 2006 by Allan Basbaum, Bruce Bean, Joyce Deleo and Tony Yaksh and is headquartered in Boston, MA.

CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA.

BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ.